Drug Trial Radar · NCT06547385
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Actual
Start
Jan 13, 2021
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
ONO-4578Drug
Specified dose on specified days
ONO-4538Drug
Specified dose on specified days
CapecitabineDrug
Specified dose on specified days
OxaliplatinDrug
Specified dose on specified days
FluorouracilDrug
Specified dose on specified days
Calcium Levofolinate HydratebDrug
Specified dose on specified days
BevacizumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of AEs and SAEsTime frame: up to 3years
- Incidence and severity of clinical laboratory abnormalitiesTime frame: up to 3years
- 12-lead electrocardiography (Heart rate)Time frame: up to 3years
- 12-lead electrocardiography (PR interval)Time frame: up to 3years
- 12-lead electrocardiography (RR interval)Time frame: up to 3years
- 12-lead electrocardiography (QRS width)Time frame: up to 3years
- 12-lead electrocardiography (QT interval)Time frame: up to 3years
- Chest X-ray testTime frame: up to 3years
- ECOG performance statusTime frame: up to 3years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
Kobe City Hospital Organization Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Saitama Cancer Center
Ina, Kitaadati-gun, Saitama, Japan
NHO Osaka National Hospital
Osaka, Osaka, Japan
Osaka General Medical Center
Osaka, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki-shi, Osaka, Japan
Saitama Medical University International Medical Center
Hidaka-shi, Saitama, Japan
Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.